BioCryst Pharmaceuticals, Inc.
NASDAQ:BCRX
Overview | Financials
Company Name | BioCryst Pharmaceuticals, Inc. |
Symbol | BCRX |
Currency | USD |
Price | 7.67 |
Market Cap | 1,586,815,620 |
Dividend Yield | 0% |
52-week-range | 4.03 - 8.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Jon P. Stonehouse |
Website | https://www.biocryst.com |
An error occurred while fetching data.
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD